lamivudine (epivir) Report issue

Small molecule Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. The most common reported adverse reactions in adults are headache, nausea, malaise and fatigue. No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.   NCATS

Chemistry

  • SMILES: NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2
  • InChIKey: JTEGQNOMFQHVDC-NKWVEPMBSA-N
  • Mol. Mass: 229.256
  • ALogP: -0.59
  • ChEMBL Molecule:
    lamivudine  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.2807 - $51.9767

Australia

$0.8465 - $43.4013
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( lamivudine (epivir), zidovudine (retrovir) )
|
( doravirine (pifeltro), tenofovir (viread), lamivudine (epivir) - other name: doravirine/lamivudine/tenofovir disoproxil fumarate 100 mg-300 mg-300 mg oral tablet [delstrigo] )
|
( dolutegravir (tivicay), lamivudine (epivir) - other names: dolutegravir 50 mg / lamivudine 300 mg oral tablet [dovato], dolutegravir/lamivudine, dolutegravir/lamivudine 50 mg-300 mg oral tablet [dovato], dolutegravir/lamivudine as a single pill, dolutegravir / lamivudine oral tablet, dolutegravir plus lamivudine in a fdc )
|
( lamivudine (epivir), raltegravir (isentress) )
|
( abacavir (ziagen), lamivudine (epivir) )
|
( tenofovir (viread), lamivudine (epivir) - other names: cimduo, temixys )
|
( efavirenz (sustiva), lamivudine (epivir), zidovudine (retrovir) )
|
( lamivudine (epivir), nevirapine (viramune), zidovudine (retrovir) - other names: lamivudine/nevirapine/zidovudine tablets, lamivudine/zidovudine 150 mg/300 mg tablets co-packaged with nevirapine 200 mg tablets, lamivudine, zidovudine tabs 150mg/300mg co-packaged with nevirapine tabs 200mg )
|
( efavirenz (sustiva), tenofovir (viread), lamivudine (epivir) - other names: efavirenz, lamivudine,and tenofovir disoproxil fumarate, symfi )
|
( abacavir (ziagen), dolutegravir (tivicay), lamivudine (epivir) )
|
( abacavir (ziagen), lamivudine (epivir), zidovudine (retrovir) - other name: abacavir sulfate; lamivudine; zidovudine )

Alternative names

(-)-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine | 2',3'-dideoxy-3'-thiacytidine | (-)-2'-deoxy-3'-thiacytidine | 3tc | 3'-thia-2',3'-dideoxycytidine | abacavir (as sulfate) / lamivudine / zidovudine | abacavir / lamivudine | abacavir sulfate / dolutegravir sodium / lamivudine | beta-l-2',3'-dideoxy-3'-thiacytidine | beta-l-3'-thia-2',3'-dideoxycytidine | combivir | epivir | epivir-hbv | gr-109714x | lamiduvine | lamivudin | lamivudina | lamivudine | lamivudine / raltegravir potassium | lamivudine / zidovudine | lamivudine / zidovudine / abacavir sulfate | lamivudinum | triomune | virolam | zeffix

Organizations (429)

Research & Development (399)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (36)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (80)

Approved Indications (5)


 

Hepatitis B

Hepatitis B, Chronic

HIV Infections

Infections

Inflammation

Experimental Indications - Clinical Trial Phases 1-4 (79)


 

Acidosis, Lactic (Phase 4)

Acquired Immunodeficiency Syndrome (Phase 4)

Aicardi Syndrome (Phase 2)

AIDS-Associated Nephropathy (Phase 3)

Allografts (Phase 4)

Alveolar Bone Loss (Phase 4)

Alzheimer Disease (Phase 1/Phase 2)

Amyotrophic Lateral Sclerosis (Phase 1/Phase 2)

Antiretroviral Therapy, Highly Active (Phase 4)

Arthralgia (Phase 3)

Atrophy (Phase 4)

Body Weight Changes (Phase 4)

Bone Diseases, Metabolic (Phase 2)

Breast Feeding (Phase 3)

Carcinoma, Hepatocellular (Phase 4)

Cardiovascular Diseases (Phase 4)

Central Nervous System Diseases (Phase 4)

Cognition Disorders (Phase 4)

Colorectal Neoplasms (Phase 2)

Dementia (Phase 4)

Diarrhea (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Drugs, Investigational (Phase 4)

Dyslipidemias (Phase 4)

Fibrosis (Phase 3)

Gender Dysphoria (Phase 1)

Glomerulonephritis (Phase 2)

Glucose Metabolism Disorders (Phase 4)

Gout (Phase 2)

Healthy Volunteers (Phase 1)

Hemophilia A (Phase 4)

Hepatitis (Phase 3)

Hepatitis B (Phase 4)

Hepatitis B, Chronic ()

Hepatitis B virus (Phase 4)

Hepatitis C (Phase 4)

Hepatitis, Chronic (Phase 4)

Hepatitis D, Chronic (Phase 2)

Herpesvirus 8, Human (Phase 4)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections ()

HIV Seropositivity (Phase 3)

Hypercholesterolemia (Phase 4)

Infections ()

Infectious Disease Transmission, Vertical (Phase 3)

Lipodystrophy (Phase 4)

Liver Cirrhosis (Phase 1/Phase 2)

Liver Cirrhosis, Biliary (Phase 2/Phase 3)

Liver Diseases (Phase 4)

Liver Failure (Phase 1/Phase 2)

Liver Neoplasms (Phase 4)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Malaria (Phase 3)

Malnutrition (Phase 4)

Medication Adherence (Early Phase 1)

Metabolic Diseases (Phase 4)

Neoplasms (Phase 3)

Obesity (Phase 4)

Organ Transplantation (Phase 4)

Osteoporosis (Phase 4)

Paraparesis, Tropical Spastic (Phase 2/Phase 3)

Patient Compliance (Phase 4)

Persistent Infection (Phase 4)

Polyarteritis Nodosa (Phase 2)

Pregnancy (Phase 3)

Pregnancy Complications (Phase 4)

Proteinuria (Phase 4)

Recurrence (Phase 4)

Renal Insufficiency (Phase 4)

Respiratory Tract Infections (Phase 1/Phase 2)

Sarcoma, Kaposi (Phase 4)

Small Cell Lung Carcinoma (Phase 2)

Transgender Persons (Phase 1)

Tuberculosis (Phase 4)

Viremia (Phase 4)

Weight Gain (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 543
  • # of Trial Organizations: 399

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue